0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative

0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Hormone Refractory Prostate Cancer (HRPCA) Market Size, Status and Forecast 2021-2027
Published Date: July 2021
|
Report Code: QYRE-Auto-28R3921
Home | Market Reports | Health | Men s Health
Global Hormone Refractory Prostate Cancer HRPCA Market Size Status and Forecast 2021 2027

Global Hormone Refractory Prostate Cancer (HRPCA) Market Size, Status and Forecast 2021-2027

Code: QYRE-Auto-28R3921
Report
July 2021
88 Pages
QYResearch
Region: Global, North America, Southeast Asia, Saudi Arabia, Turkey, UAE, Europe, France, Canada, Germany, Italy, Russia, South Korea,
Description
Table of Content
Tables & Figures
Hormone Refractory Prostate Cancer (HRPCA) or Castrate-Resistant Prostate Cancer (CRPC), a type of prostate cancer that typically recurs after having hormonal Therapy, is now under the spotlight in prostate cancer market. Due to the high unmet clinical need associated with limited survival periods, intensifying HRPCA prevalence and fast-emerging treatment modifications, the global HRPCA market is poised to witness an unprecedented growth.
Market Analysis and Insights: Global Hormone Refractory Prostate Cancer (HRPCA) Market
The global Hormone Refractory Prostate Cancer (HRPCA) market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Hormone Refractory Prostate Cancer (HRPCA) market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Hormone Refractory Prostate Cancer (HRPCA) market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Hormone Refractory Prostate Cancer (HRPCA) market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Hormone Refractory Prostate Cancer (HRPCA) market.
Global Hormone Refractory Prostate Cancer (HRPCA) Scope and Market Size
Hormone Refractory Prostate Cancer (HRPCA) market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Hormone Refractory Prostate Cancer (HRPCA) market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type

Cytotoxic Agents
Anti-Androgens
Vaccines
Radio-Pharmaceuticals

Segment by Application

Hospitals
Ambulatory Surgical Centers
Specialty Clinics
Others

BY REGION

North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

BY COMPANY

Astellas Inc
Sanofi S.A
Dendreon Corporation, Bayer AG
Johnson & Johnson
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Hormone Refractory Prostate Cancer (HRPCA) Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Cytotoxic Agents
1.2.3 Anti-Androgens
1.2.4 Vaccines
1.2.5 Radio-Pharmaceuticals
1.3 Market by Application
1.3.1 Global Hormone Refractory Prostate Cancer (HRPCA) Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Hospitals
1.3.3 Ambulatory Surgical Centers
1.3.4 Specialty Clinics
1.3.5 Others
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Hormone Refractory Prostate Cancer (HRPCA) Market Perspective (2016-2027)
2.2 Hormone Refractory Prostate Cancer (HRPCA) Growth Trends by Regions
2.2.1 Hormone Refractory Prostate Cancer (HRPCA) Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Hormone Refractory Prostate Cancer (HRPCA) Historic Market Share by Regions (2016-2021)
2.2.3 Hormone Refractory Prostate Cancer (HRPCA) Forecasted Market Size by Regions (2022-2027)
2.3 Hormone Refractory Prostate Cancer (HRPCA) Industry Dynamic
2.3.1 Hormone Refractory Prostate Cancer (HRPCA) Market Trends
2.3.2 Hormone Refractory Prostate Cancer (HRPCA) Market Drivers
2.3.3 Hormone Refractory Prostate Cancer (HRPCA) Market Challenges
2.3.4 Hormone Refractory Prostate Cancer (HRPCA) Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Hormone Refractory Prostate Cancer (HRPCA) Players by Revenue
3.1.1 Global Top Hormone Refractory Prostate Cancer (HRPCA) Players by Revenue (2016-2021)
3.1.2 Global Hormone Refractory Prostate Cancer (HRPCA) Revenue Market Share by Players (2016-2021)
3.2 Global Hormone Refractory Prostate Cancer (HRPCA) Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Hormone Refractory Prostate Cancer (HRPCA) Revenue
3.4 Global Hormone Refractory Prostate Cancer (HRPCA) Market Concentration Ratio
3.4.1 Global Hormone Refractory Prostate Cancer (HRPCA) Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Hormone Refractory Prostate Cancer (HRPCA) Revenue in 2020
3.5 Hormone Refractory Prostate Cancer (HRPCA) Key Players Head office and Area Served
3.6 Key Players Hormone Refractory Prostate Cancer (HRPCA) Product Solution and Service
3.7 Date of Enter into Hormone Refractory Prostate Cancer (HRPCA) Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Hormone Refractory Prostate Cancer (HRPCA) Breakdown Data by Type
4.1 Global Hormone Refractory Prostate Cancer (HRPCA) Historic Market Size by Type (2016-2021)
4.2 Global Hormone Refractory Prostate Cancer (HRPCA) Forecasted Market Size by Type (2022-2027)
5 Hormone Refractory Prostate Cancer (HRPCA) Breakdown Data by Application
5.1 Global Hormone Refractory Prostate Cancer (HRPCA) Historic Market Size by Application (2016-2021)
5.2 Global Hormone Refractory Prostate Cancer (HRPCA) Forecasted Market Size by Application (2022-2027)
6 North America
6.1 North America Hormone Refractory Prostate Cancer (HRPCA) Market Size (2016-2027)
6.2 North America Hormone Refractory Prostate Cancer (HRPCA) Market Size by Type
6.2.1 North America Hormone Refractory Prostate Cancer (HRPCA) Market Size by Type (2016-2021)
6.2.2 North America Hormone Refractory Prostate Cancer (HRPCA) Market Size by Type (2022-2027)
6.2.3 North America Hormone Refractory Prostate Cancer (HRPCA) Market Size by Type (2016-2027)
6.3 North America Hormone Refractory Prostate Cancer (HRPCA) Market Size by Application
6.3.1 North America Hormone Refractory Prostate Cancer (HRPCA) Market Size by Application (2016-2021)
6.3.2 North America Hormone Refractory Prostate Cancer (HRPCA) Market Size by Application (2022-2027)
6.3.3 North America Hormone Refractory Prostate Cancer (HRPCA) Market Size by Application (2016-2027)
6.4 North America Hormone Refractory Prostate Cancer (HRPCA) Market Size by Country
6.4.1 North America Hormone Refractory Prostate Cancer (HRPCA) Market Size by Country (2016-2021)
6.4.2 North America Hormone Refractory Prostate Cancer (HRPCA) Market Size by Country (2022-2027)
6.4.3 United States
6.4.4 Canada
7 Europe
7.1 Europe Hormone Refractory Prostate Cancer (HRPCA) Market Size (2016-2027)
7.2 Europe Hormone Refractory Prostate Cancer (HRPCA) Market Size by Type
7.2.1 Europe Hormone Refractory Prostate Cancer (HRPCA) Market Size by Type (2016-2021)
7.2.2 Europe Hormone Refractory Prostate Cancer (HRPCA) Market Size by Type (2022-2027)
7.2.3 Europe Hormone Refractory Prostate Cancer (HRPCA) Market Size by Type (2016-2027)
7.3 Europe Hormone Refractory Prostate Cancer (HRPCA) Market Size by Application
7.3.1 Europe Hormone Refractory Prostate Cancer (HRPCA) Market Size by Application (2016-2021)
7.3.2 Europe Hormone Refractory Prostate Cancer (HRPCA) Market Size by Application (2022-2027)
7.3.3 Europe Hormone Refractory Prostate Cancer (HRPCA) Market Size by Application (2016-2027)
7.4 Europe Hormone Refractory Prostate Cancer (HRPCA) Market Size by Country
7.4.1 Europe Hormone Refractory Prostate Cancer (HRPCA) Market Size by Country (2016-2021)
7.4.2 Europe Hormone Refractory Prostate Cancer (HRPCA) Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic
8 Asia-Pacific
8.1 Asia-Pacific Hormone Refractory Prostate Cancer (HRPCA) Market Size (2016-2027)
8.2 Asia-Pacific Hormone Refractory Prostate Cancer (HRPCA) Market Size by Type
8.2.1 Asia-Pacific Hormone Refractory Prostate Cancer (HRPCA) Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Hormone Refractory Prostate Cancer (HRPCA) Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Hormone Refractory Prostate Cancer (HRPCA) Market Size by Type (2016-2027)
8.3 Asia-Pacific Hormone Refractory Prostate Cancer (HRPCA) Market Size by Application
8.3.1 Asia-Pacific Hormone Refractory Prostate Cancer (HRPCA) Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Hormone Refractory Prostate Cancer (HRPCA) Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Hormone Refractory Prostate Cancer (HRPCA) Market Size by Application (2016-2027)
8.4 Asia-Pacific Hormone Refractory Prostate Cancer (HRPCA) Market Size by Region
8.4.1 Asia-Pacific Hormone Refractory Prostate Cancer (HRPCA) Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Hormone Refractory Prostate Cancer (HRPCA) Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia
9 Latin America
9.1 Latin America Hormone Refractory Prostate Cancer (HRPCA) Market Size (2016-2027)
9.2 Latin America Hormone Refractory Prostate Cancer (HRPCA) Market Size by Type
9.2.1 Latin America Hormone Refractory Prostate Cancer (HRPCA) Market Size by Type (2016-2021)
9.2.2 Latin America Hormone Refractory Prostate Cancer (HRPCA) Market Size by Type (2022-2027)
9.2.3 Latin America Hormone Refractory Prostate Cancer (HRPCA) Market Size by Type (2016-2027)
9.3 Latin America Hormone Refractory Prostate Cancer (HRPCA) Market Size by Application
9.3.1 Latin America Hormone Refractory Prostate Cancer (HRPCA) Market Size by Application (2016-2021)
9.3.2 Latin America Hormone Refractory Prostate Cancer (HRPCA) Market Size by Application (2022-2027)
9.3.3 Latin America Hormone Refractory Prostate Cancer (HRPCA) Market Size by Application (2016-2027)
9.4 Latin America Hormone Refractory Prostate Cancer (HRPCA) Market Size by Country
9.4.1 Latin America Hormone Refractory Prostate Cancer (HRPCA) Market Size by Country (2016-2021)
9.4.2 Latin America Hormone Refractory Prostate Cancer (HRPCA) Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Hormone Refractory Prostate Cancer (HRPCA) Market Size (2016-2027)
10.2 Middle East & Africa Hormone Refractory Prostate Cancer (HRPCA) Market Size by Type
10.2.1 Middle East & Africa Hormone Refractory Prostate Cancer (HRPCA) Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Hormone Refractory Prostate Cancer (HRPCA) Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Hormone Refractory Prostate Cancer (HRPCA) Market Size by Type (2016-2027)
10.3 Middle East & Africa Hormone Refractory Prostate Cancer (HRPCA) Market Size by Application
10.3.1 Middle East & Africa Hormone Refractory Prostate Cancer (HRPCA) Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Hormone Refractory Prostate Cancer (HRPCA) Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Hormone Refractory Prostate Cancer (HRPCA) Market Size by Application (2016-2027)
10.4 Middle East & Africa Hormone Refractory Prostate Cancer (HRPCA) Market Size by Country
10.4.1 Middle East & Africa Hormone Refractory Prostate Cancer (HRPCA) Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Hormone Refractory Prostate Cancer (HRPCA) Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE
11 Key Players Profiles
11.1 Astellas Inc
11.1.1 Astellas Inc Company Details
11.1.2 Astellas Inc Business Overview
11.1.3 Astellas Inc Hormone Refractory Prostate Cancer (HRPCA) Introduction
11.1.4 Astellas Inc Revenue in Hormone Refractory Prostate Cancer (HRPCA) Business (2016-2021)
11.1.5 Astellas Inc Recent Development
11.2 Sanofi S.A
11.2.1 Sanofi S.A Company Details
11.2.2 Sanofi S.A Business Overview
11.2.3 Sanofi S.A Hormone Refractory Prostate Cancer (HRPCA) Introduction
11.2.4 Sanofi S.A Revenue in Hormone Refractory Prostate Cancer (HRPCA) Business (2016-2021)
11.2.5 Sanofi S.A Recent Development
11.3 Dendreon Corporation, Bayer AG
11.3.1 Dendreon Corporation, Bayer AG Company Details
11.3.2 Dendreon Corporation, Bayer AG Business Overview
11.3.3 Dendreon Corporation, Bayer AG Hormone Refractory Prostate Cancer (HRPCA) Introduction
11.3.4 Dendreon Corporation, Bayer AG Revenue in Hormone Refractory Prostate Cancer (HRPCA) Business (2016-2021)
11.3.5 Dendreon Corporation, Bayer AG Recent Development
11.4 Johnson & Johnson
11.4.1 Johnson & Johnson Company Details
11.4.2 Johnson & Johnson Business Overview
11.4.3 Johnson & Johnson Hormone Refractory Prostate Cancer (HRPCA) Introduction
11.4.4 Johnson & Johnson Revenue in Hormone Refractory Prostate Cancer (HRPCA) Business (2016-2021)
11.4.5 Johnson & Johnson Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of Tables
    Table 1. Global Hormone Refractory Prostate Cancer (HRPCA) Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
    Table 2. Key Players of Cytotoxic Agents
    Table 3. Key Players of Anti-Androgens
    Table 4. Key Players of Vaccines
    Table 5. Key Players of Radio-Pharmaceuticals
    Table 6. Global Hormone Refractory Prostate Cancer (HRPCA) Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
    Table 7. Global Hormone Refractory Prostate Cancer (HRPCA) Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
    Table 8. Global Hormone Refractory Prostate Cancer (HRPCA) Market Size by Regions (2016-2021) & (US$ Million)
    Table 9. Global Hormone Refractory Prostate Cancer (HRPCA) Market Share by Regions (2016-2021)
    Table 10. Global Hormone Refractory Prostate Cancer (HRPCA) Forecasted Market Size by Regions (2022-2027) & (US$ Million)
    Table 11. Global Hormone Refractory Prostate Cancer (HRPCA) Market Share by Regions (2022-2027)
    Table 12. Hormone Refractory Prostate Cancer (HRPCA) Market Trends
    Table 13. Hormone Refractory Prostate Cancer (HRPCA) Market Drivers
    Table 14. Hormone Refractory Prostate Cancer (HRPCA) Market Challenges
    Table 15. Hormone Refractory Prostate Cancer (HRPCA) Market Restraints
    Table 16. Global Hormone Refractory Prostate Cancer (HRPCA) Revenue by Players (2016-2021) & (US$ Million)
    Table 17. Global Hormone Refractory Prostate Cancer (HRPCA) Market Share by Players (2016-2021)
    Table 18. Global Top Hormone Refractory Prostate Cancer (HRPCA) Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Hormone Refractory Prostate Cancer (HRPCA) as of 2020)
    Table 19. Ranking of Global Top Hormone Refractory Prostate Cancer (HRPCA) Companies by Revenue (US$ Million) in 2020
    Table 20. Global 5 Largest Players Market Share by Hormone Refractory Prostate Cancer (HRPCA) Revenue (CR5 and HHI) & (2016-2021)
    Table 21. Key Players Headquarters and Area Served
    Table 22. Key Players Hormone Refractory Prostate Cancer (HRPCA) Product Solution and Service
    Table 23. Date of Enter into Hormone Refractory Prostate Cancer (HRPCA) Market
    Table 24. Mergers & Acquisitions, Expansion Plans
    Table 25. Global Hormone Refractory Prostate Cancer (HRPCA) Market Size by Type (2016-2021) (US$ Million)
    Table 26. Global Hormone Refractory Prostate Cancer (HRPCA) Revenue Market Share by Type (2016-2021)
    Table 27. Global Hormone Refractory Prostate Cancer (HRPCA) Forecasted Market Size by Type (2022-2027) (US$ Million)
    Table 28. Global Hormone Refractory Prostate Cancer (HRPCA) Revenue Market Share by Type (2022-2027) & (US$ Million)
    Table 29. Global Hormone Refractory Prostate Cancer (HRPCA) Market Size Share by Application (2016-2021) & (US$ Million)
    Table 30. Global Hormone Refractory Prostate Cancer (HRPCA) Revenue Market Share by Application (2016-2021)
    Table 31. Global Hormone Refractory Prostate Cancer (HRPCA) Forecasted Market Size by Application (2022-2027) (US$ Million)
    Table 32. Global Hormone Refractory Prostate Cancer (HRPCA) Revenue Market Share by Application (2022-2027) & (US$ Million)
    Table 33. North America Hormone Refractory Prostate Cancer (HRPCA) Market Size by Type (2016-2021) (US$ Million)
    Table 34. North America Hormone Refractory Prostate Cancer (HRPCA) Market Size by Type (2022-2027) & (US$ Million)
    Table 35. North America Hormone Refractory Prostate Cancer (HRPCA) Market Size by Application (2016-2021) (US$ Million)
    Table 36. North America Hormone Refractory Prostate Cancer (HRPCA) Market Size by Application (2022-2027) & (US$ Million)
    Table 37. North America Hormone Refractory Prostate Cancer (HRPCA) Market Size by Country (2016-2021) & (US$ Million)
    Table 38. North America Hormone Refractory Prostate Cancer (HRPCA) Market Size by Country (2022-2027) & (US$ Million)
    Table 39. Europe Hormone Refractory Prostate Cancer (HRPCA) Market Size by Type (2016-2021) (US$ Million)
    Table 40. Europe Hormone Refractory Prostate Cancer (HRPCA) Market Size by Type (2022-2027) & (US$ Million)
    Table 41. Europe Hormone Refractory Prostate Cancer (HRPCA) Market Size by Application (2016-2021) (US$ Million)
    Table 42. Europe Hormone Refractory Prostate Cancer (HRPCA) Market Size by Application (2022-2027) & (US$ Million)
    Table 43. Europe Hormone Refractory Prostate Cancer (HRPCA) Market Size by Country (2016-2021) & (US$ Million)
    Table 44. Europe Hormone Refractory Prostate Cancer (HRPCA) Market Size by Country (2022-2027) & (US$ Million)
    Table 45. Asia-Pacific Hormone Refractory Prostate Cancer (HRPCA) Market Size by Type (2016-2021) (US$ Million)
    Table 46. Asia-Pacific Hormone Refractory Prostate Cancer (HRPCA) Market Size by Type (2022-2027) & (US$ Million)
    Table 47. Asia-Pacific Hormone Refractory Prostate Cancer (HRPCA) Market Size by Application (2016-2021) (US$ Million)
    Table 48. Asia-Pacific Hormone Refractory Prostate Cancer (HRPCA) Market Size by Application (2022-2027) & (US$ Million)
    Table 49. Asia-Pacific Hormone Refractory Prostate Cancer (HRPCA) Market Size by Region (2016-2021) & (US$ Million)
    Table 50. Asia-Pacific Hormone Refractory Prostate Cancer (HRPCA) Market Size by Region (2022-2027) & (US$ Million)
    Table 51. Latin America Hormone Refractory Prostate Cancer (HRPCA) Market Size by Type (2016-2021) (US$ Million)
    Table 52. Latin America Hormone Refractory Prostate Cancer (HRPCA) Market Size by Type (2022-2027) & (US$ Million)
    Table 53. Latin America Hormone Refractory Prostate Cancer (HRPCA) Market Size by Application (2016-2021) (US$ Million)
    Table 54. Latin America Hormone Refractory Prostate Cancer (HRPCA) Market Size by Application (2022-2027) & (US$ Million)
    Table 55. Latin America Hormone Refractory Prostate Cancer (HRPCA) Market Size by Country (2016-2021) & (US$ Million)
    Table 56. Latin America Hormone Refractory Prostate Cancer (HRPCA) Market Size by Country (2022-2027) & (US$ Million)
    Table 57. Middle East & Africa Hormone Refractory Prostate Cancer (HRPCA) Market Size by Type (2016-2021) (US$ Million)
    Table 58. Middle East & Africa Hormone Refractory Prostate Cancer (HRPCA) Market Size by Type (2022-2027) & (US$ Million)
    Table 59. Middle East & Africa Hormone Refractory Prostate Cancer (HRPCA) Market Size by Application (2016-2021) (US$ Million)
    Table 60. Middle East & Africa Hormone Refractory Prostate Cancer (HRPCA) Market Size by Application (2022-2027) & (US$ Million)
    Table 61. Middle East & Africa Hormone Refractory Prostate Cancer (HRPCA) Market Size by Country (2016-2021) & (US$ Million)
    Table 62. Middle East & Africa Hormone Refractory Prostate Cancer (HRPCA) Market Size by Country (2022-2027) & (US$ Million)
    Table 63. Astellas Inc Company Details
    Table 64. Astellas Inc Business Overview
    Table 65. Astellas Inc Hormone Refractory Prostate Cancer (HRPCA) Product
    Table 66. Astellas Inc Revenue in Hormone Refractory Prostate Cancer (HRPCA) Business (2016-2021) & (US$ Million)
    Table 67. Astellas Inc Recent Development
    Table 68. Sanofi S.A Company Details
    Table 69. Sanofi S.A Business Overview
    Table 70. Sanofi S.A Hormone Refractory Prostate Cancer (HRPCA) Product
    Table 71. Sanofi S.A Revenue in Hormone Refractory Prostate Cancer (HRPCA) Business (2016-2021) & (US$ Million)
    Table 72. Sanofi S.A Recent Development
    Table 73. Dendreon Corporation, Bayer AG Company Details
    Table 74. Dendreon Corporation, Bayer AG Business Overview
    Table 75. Dendreon Corporation, Bayer AG Hormone Refractory Prostate Cancer (HRPCA) Product
    Table 76. Dendreon Corporation, Bayer AG Revenue in Hormone Refractory Prostate Cancer (HRPCA) Business (2016-2021) & (US$ Million)
    Table 77. Dendreon Corporation, Bayer AG Recent Development
    Table 78. Johnson & Johnson Company Details
    Table 79. Johnson & Johnson Business Overview
    Table 80. Johnson & Johnson Hormone Refractory Prostate Cancer (HRPCA) Product
    Table 81. Johnson & Johnson Revenue in Hormone Refractory Prostate Cancer (HRPCA) Business (2016-2021) & (US$ Million)
    Table 82. Johnson & Johnson Recent Development
    Table 83. Research Programs/Design for This Report
    Table 84. Key Data Information from Secondary Sources
    Table 85. Key Data Information from Primary Sources
List of Figures
    Figure 1. Global Hormone Refractory Prostate Cancer (HRPCA) Market Share by Type: 2020 VS 2027
    Figure 2. Cytotoxic Agents Features
    Figure 3. Anti-Androgens Features
    Figure 4. Vaccines Features
    Figure 5. Radio-Pharmaceuticals Features
    Figure 6. Global Hormone Refractory Prostate Cancer (HRPCA) Market Share by Application: 2020 VS 2027
    Figure 7. Hospitals Case Studies
    Figure 8. Ambulatory Surgical Centers Case Studies
    Figure 9. Specialty Clinics Case Studies
    Figure 10. Others Case Studies
    Figure 11. Hormone Refractory Prostate Cancer (HRPCA) Report Years Considered
    Figure 12. Global Hormone Refractory Prostate Cancer (HRPCA) Market Size (US$ Million), Year-over-Year: 2016-2027
    Figure 13. Global Hormone Refractory Prostate Cancer (HRPCA) Market Size (US$ Million), 2016 VS 2021 VS 2027
    Figure 14. Global Hormone Refractory Prostate Cancer (HRPCA) Market Share by Regions: 2020 VS 2027
    Figure 15. Global Hormone Refractory Prostate Cancer (HRPCA) Market Share by Regions (2022-2027)
    Figure 16. Global Hormone Refractory Prostate Cancer (HRPCA) Market Share by Players in 2020
    Figure 17. Global Top Hormone Refractory Prostate Cancer (HRPCA) Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Hormone Refractory Prostate Cancer (HRPCA) as of 2020
    Figure 18. The Top 10 and 5 Players Market Share by Hormone Refractory Prostate Cancer (HRPCA) Revenue in 2020
    Figure 19. Global Hormone Refractory Prostate Cancer (HRPCA) Revenue Market Share by Type (2016-2021)
    Figure 20. Global Hormone Refractory Prostate Cancer (HRPCA) Revenue Market Share by Type (2022-2027)
    Figure 21. North America Hormone Refractory Prostate Cancer (HRPCA) Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 22. North America Hormone Refractory Prostate Cancer (HRPCA) Market Share by Type (2016-2027)
    Figure 23. North America Hormone Refractory Prostate Cancer (HRPCA) Market Share by Application (2016-2027)
    Figure 24. North America Hormone Refractory Prostate Cancer (HRPCA) Market Share by Country (2016-2027)
    Figure 25. United States Hormone Refractory Prostate Cancer (HRPCA) Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 26. Canada Hormone Refractory Prostate Cancer (HRPCA) Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 27. Europe Hormone Refractory Prostate Cancer (HRPCA) Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 28. Europe Hormone Refractory Prostate Cancer (HRPCA) Market Share by Type (2016-2027)
    Figure 29. Europe Hormone Refractory Prostate Cancer (HRPCA) Market Share by Application (2016-2027)
    Figure 30. Europe Hormone Refractory Prostate Cancer (HRPCA) Market Share by Country (2016-2027)
    Figure 31. Germany Hormone Refractory Prostate Cancer (HRPCA) Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 32. France Hormone Refractory Prostate Cancer (HRPCA) Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 33. U.K. Hormone Refractory Prostate Cancer (HRPCA) Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 34. Italy Hormone Refractory Prostate Cancer (HRPCA) Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 35. Russia Hormone Refractory Prostate Cancer (HRPCA) Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 36. Nordic Hormone Refractory Prostate Cancer (HRPCA) Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 37. Asia-Pacific Hormone Refractory Prostate Cancer (HRPCA) Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 38. Asia-Pacific Hormone Refractory Prostate Cancer (HRPCA) Market Share by Type (2016-2027)
    Figure 39. Asia-Pacific Hormone Refractory Prostate Cancer (HRPCA) Market Share by Application (2016-2027)
    Figure 40. Asia-Pacific Hormone Refractory Prostate Cancer (HRPCA) Market Share by Region (2016-2027)
    Figure 41. China Hormone Refractory Prostate Cancer (HRPCA) Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 42. Japan Hormone Refractory Prostate Cancer (HRPCA) Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 43. South Korea Hormone Refractory Prostate Cancer (HRPCA) Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 44. Southeast Asia Hormone Refractory Prostate Cancer (HRPCA) Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 45. India Hormone Refractory Prostate Cancer (HRPCA) Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 46. Australia Hormone Refractory Prostate Cancer (HRPCA) Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 47. Latin America Hormone Refractory Prostate Cancer (HRPCA) Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 48. Latin America Hormone Refractory Prostate Cancer (HRPCA) Market Share by Type (2016-2027)
    Figure 49. Latin America Hormone Refractory Prostate Cancer (HRPCA) Market Share by Application (2016-2027)
    Figure 50. Latin America Hormone Refractory Prostate Cancer (HRPCA) Market Share by Country (2016-2027)
    Figure 51. Mexico Hormone Refractory Prostate Cancer (HRPCA) Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 52. Brazil Hormone Refractory Prostate Cancer (HRPCA) Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 53. Middle East & Africa Hormone Refractory Prostate Cancer (HRPCA) Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 54. Middle East & Africa Hormone Refractory Prostate Cancer (HRPCA) Market Share by Type (2016-2027)
    Figure 55. Middle East & Africa Hormone Refractory Prostate Cancer (HRPCA) Market Share by Application (2016-2027)
    Figure 56. Middle East & Africa Hormone Refractory Prostate Cancer (HRPCA) Market Share by Country (2016-2027)
    Figure 57. Turkey Hormone Refractory Prostate Cancer (HRPCA) Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 58. Saudi Arabia Hormone Refractory Prostate Cancer (HRPCA) Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 59. UAE Hormone Refractory Prostate Cancer (HRPCA) Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 60. Astellas Inc Revenue Growth Rate in Hormone Refractory Prostate Cancer (HRPCA) Business (2016-2021)
    Figure 61. Sanofi S.A Revenue Growth Rate in Hormone Refractory Prostate Cancer (HRPCA) Business (2016-2021)
    Figure 62. Dendreon Corporation, Bayer AG Revenue Growth Rate in Hormone Refractory Prostate Cancer (HRPCA) Business (2016-2021)
    Figure 63. Johnson & Johnson Revenue Growth Rate in Hormone Refractory Prostate Cancer (HRPCA) Business (2016-2021)
    Figure 64. Bottom-up and Top-down Approaches for This Report
    Figure 65. Data Triangulation
    Figure 66. Key Executives Interviewed
SELECT A FORMAT
Added to Cart

Electronic (PDF)
$3900
This license allows only one user(purchaser of the report) to access the PDF.

Electronic (PDF)
$5850
This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Electronic (PDF)
$7800
This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (10% Discount)
OUR CUSTOMER
Leap India